{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:12:53Z","timestamp":1780791173864,"version":"3.54.1"},"reference-count":44,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"4","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: This study aims to investigate the relationship between proprotein convertase subtilisin\/ kexin type 9 (PCSK9) levels and subclinical atherosclerosis (SA) in patients with ankylosing spondylitis (AS).\r\nPatients and methods: Between January 2022 and March 2022, a total of 56 patients (33 males, 23 females; mean age: 37.8\u00b19.3 years; range, 20 to 60 years) who were under regular follow-up in our clinic and fulfilled the criteria of the Modified New York Diagnostic Criteria for AS and American College of Rheumatology (ACR) for AS were included. Age- and sex-matched 56 healthy volunteers (25 males, 31 females; mean age: 38.4\u00b18.2 years; range, 20 to 60 years) were also recruited as the control group. Demographic, clinical, and laboratory data were recorded. The PCSK9 level and carotid intima-media thickness (cIMT) were evaluated using appropriate methods.\r\nResults: The mean serum PCSK9 levels in AS patients (609.3\u00b1149.9 vs. 136.3\u00b1120.8 ng\/mL, p<\/jats:p>","DOI":"10.46497\/archrheumatol.2024.10625","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:56:27Z","timestamp":1740988587000},"page":"652-661","source":"Crossref","is-referenced-by-count":2,"title":["Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis"],"prefix":"10.5152","volume":"39","author":[{"family":"Ahmet Karakoyun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yasemin Akkubak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mevl\u00fct Hakan G\u00f6ktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"P\u0131nar Diydem Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cengiz Kad\u0131yoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mustafa O\u011ful","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Adem Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref-1","unstructured":"Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, et al. Ankylosing spondylitis: Etiology, pathogenesis, and treatments. Bone Res 2019;7:22. doi: 10.1038\/ s41413-019-0057-8."},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650-7. doi: 10.1093\/rheumatology\/ket387.","DOI":"10.1093\/rheumatology\/ket387"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Haroon NN, Paterson JM, Li P, Haroon N. Increasing proportion of female patients with ankylosing spondylitis: A population-based study of trends in the incidence and prevalence of AS. BMJ Open 2014;4:e006634. doi: 10.1136\/ bmjopen-2014-006634.","DOI":"10.1136\/bmjopen-2014-006634"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48:1029-35. doi: 10.1093\/rheumatology\/kep146.","DOI":"10.1093\/rheumatology\/kep146"},{"key":"ref-5","unstructured":"Giray E, Ya\u011fc\u0131 \u2039. Cardiac rehabilitation in a patient with ankylosing spondylitis: A single-program, doubleeffect. Turk J Phys Med Rehabil 2018;65:194-7. doi: 10.5606\/tftrd.2019.2401."},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Verma I, Krishan P, Syngle A. Predictors of atherosclerosis in ankylosing spondylitis. Rheumatol Ther 2015;2:173-82. doi: 10.1007\/s40744-015- 0017-8.","DOI":"10.1007\/s40744-015-0017-8"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Ozkan Y. Cardiac involvement in ankylosing spondylitis. J Clin Med Res 2016;8:427-30. doi: 10.14740\/jocmr2488w.","DOI":"10.14740\/jocmr2488w"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Kasliwal RR, Bansal M, Desai D, Sharma M. Carotid intima-media thickness: Current evidence, practices, and Indian experience. Indian J Endocrinol Metab 2014;18:13-22. doi: 10.4103\/2230-8210.126522.","DOI":"10.4103\/2230-8210.126522"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"\u0141oboz-Rudnicka M, Jaroch J, Boci\u0105ga Z, Rzyczkowska B, Uchmanowicz I, Pola\u0144ski J, et al. Impact of cardiovascular risk factors on carotid intima-media thickness: Sex differences. Clin Interv Aging 2016;11:721-31. doi: 10.2147\/CIA. S103521.","DOI":"10.2147\/CIA.S103521"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci 2018;19:1890. doi: 10.3390\/ ijms19071890.","DOI":"10.3390\/ijms19071890"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: A systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30:1014-26. doi: 10.1161\/ ATVBAHA.109.198424.","DOI":"10.1161\/ATVBAHA.109.198424"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res 2009;50 Suppl:S172-7. doi: 10.1194\/jlr. R800091-JLR200.","DOI":"10.1194\/jlr.R800091-JLR200"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol 2018;15:52-62. doi: 10.1038\/ s41574-018-0110-5.","DOI":"10.1038\/s41574-018-0110-5"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Lagace TA. PCSK9 and LDLR degradation: Regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 2014;25:387-93. doi: 10.1097\/ MOL.0000000000000114.","DOI":"10.1097\/MOL.0000000000000114"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Shapiro MD, Fazio S. PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb 2017;24:462- 72. doi: 10.5551\/jat.RV17003.","DOI":"10.5551\/jat.RV17003"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Tveten K, Str M TB, Berge KE, Leren TP. PCSK9- mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. J Lipid Res 2013;54:1560-6. doi: 10.1194\/jlr.M034371.","DOI":"10.1194\/jlr.M034371"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 targeting: Alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 2022;11:e023328. doi: 10.1161\/ JAHA.121.023328.","DOI":"10.1161\/JAHA.121.023328"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Zhong Z, Feng X, Su G, Du L, Liao W, Liu S, et al. HMG-Coenzyme a reductase as a drug target for the prevention of ankylosing spondylitis. Front Cell Dev Biol 2021;9:731072. doi: 10.3389\/fcell.2021.731072.","DOI":"10.3389\/fcell.2021.731072"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"de Armas-Rillo L, Quevedo-Abeledo JC, de Vera-Gonz\u00e1lez A, Gonz\u00e1lez-Delgado A, Garc\u00eda-Dopico JA, Jimenez-Sosa A, et al. Proprotein convertase subtilisin\/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. Rheumatology (Oxford) 2021;60:2296-306. doi: 10.1093\/rheumatology\/keaa590.","DOI":"10.1093\/rheumatology\/keaa590"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing spondylitis. J Ophthalmic Vis Res 2021;16:462-9. doi: 10.18502\/jovr.v16i3.9440.","DOI":"10.18502\/jovr.v16i3.9440"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? J Am Coll Cardiol 2013;62:397-408. doi: 10.1016\/j.jacc.2013.05.016.","DOI":"10.1016\/j.jacc.2013.05.016"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004;18:346-9. doi: 10.1159\/000081812.","DOI":"10.1159\/000081812"},{"key":"ref-23","doi-asserted-by":"crossref","unstructured":"Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111. doi: 10.1016\/j. echo.2007.11.011.","DOI":"10.1016\/j.echo.2007.11.011"},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Gonzalez J, Wood JC, Dorey FJ, Wren TA, Gilsanz V. Reproducibility of carotid intima-media thickness measurements in young adults. Radiology 2008;247:465-71. doi: 10.1148\/radiol.2472070691.","DOI":"10.1148\/radiol.2472070691"},{"key":"ref-25","doi-asserted-by":"crossref","unstructured":"Aydogan Baykara R, Yilmaz PD, G\u00f6ktepe MH, Kadiyoran C, Ogul M, Kucuk A, et al. Proprotein convertase subtilisin\/kexin type 9 is associated with atherosclerosis in patients with Behcet\u2019s disease. Clin Exp Hypertens 2022;44:480-6. doi: 10.1080\/10641963.2022.2071921.","DOI":"10.1080\/10641963.2022.2071921"},{"key":"ref-26","doi-asserted-by":"crossref","unstructured":"Toussirot E. The risk of cardiovascular diseases in axial spondyloarthritis. Current insights. Front Med (Lausanne) 2021;8:782150. doi: 10.3389\/ fmed.2021.782150.","DOI":"10.3389\/fmed.2021.782150"},{"key":"ref-27","doi-asserted-by":"crossref","unstructured":"Bai R, Zhang Y, Liu W, Ma C, Chen X, Yang J, et al. The relationship of ankylosing spondylitis and subclinical atherosclerosis: A Systemic review and meta-analysis. Angiology. 2019;70:492-500. doi: 10.1177\/0003319718814309.","DOI":"10.1177\/0003319718814309"},{"key":"ref-28","doi-asserted-by":"crossref","unstructured":"Mathieu S, Soubrier M. Cardiovascular events in ankylosing spondylitis: A 2018 meta-analysis. Ann Rheum Dis 2019;78:e57. doi: 10.1136\/ annrheumdis-2018-213317.","DOI":"10.1136\/annrheumdis-2018-213317"},{"key":"ref-29","doi-asserted-by":"crossref","unstructured":"Ionescu M, Ionescu P, Suceveanu AP, Stoian AP, Motofei I, Ardeleanu V, et al. Cardiovascular risk estimation in young patients with ankylosing spondylitis: A new model based on a prospective study in Constanta County, Romania. Exp Ther Med 2021;21:529. doi: 10.3892\/etm.2021.9961.","DOI":"10.3892\/etm.2021.9961"},{"key":"ref-30","doi-asserted-by":"crossref","unstructured":"Adua E, Memarian E, Russell A, Trbojevi\u0107-Akma\u010di\u0107 I, Gudelj I, Juri\u0107 J, et al. High throughput profiling of whole plasma N-glycans in type II diabetes mellitus patients and healthy individuals: A perspective from a Ghanaian population. Arch Biochem Biophys 2019;661:10-21. doi: 10.1016\/j.abb.2018.10.015.","DOI":"10.1016\/j.abb.2018.10.015"},{"key":"ref-31","doi-asserted-by":"crossref","unstructured":"Sundararaman SS, D\u00f6ring Y, van der Vorst EPC. PCSK9: A multi-faceted protein that is involved in cardiovascular biology. Biomedicines 2021;9:793. doi: 10.3390\/biomedicines9070793.","DOI":"10.3390\/biomedicines9070793"},{"key":"ref-32","doi-asserted-by":"crossref","unstructured":"Wu NQ, Shi HW, Li JJ. Proprotein convertase subtilisin\/kexin type 9 and inflammation: An updated review. Front Cardiovasc Med 2022;9:763516. doi: 10.3389\/fcvm.2022.763516.","DOI":"10.3389\/fcvm.2022.763516"},{"key":"ref-33","doi-asserted-by":"crossref","unstructured":"Cammisotto V, Baratta F, Simeone PG, Barale C, Lupia E, Galardo G, et al. Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) beyond lipids: The role in oxidative stress and thrombosis. Antioxidants (Basel) 2022;11:569. doi: 10.3390\/antiox11030569.","DOI":"10.3390\/antiox11030569"},{"key":"ref-34","doi-asserted-by":"crossref","unstructured":"Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med 2015;47:386-93. doi: 10.3109\/07853890.2015.1042908.","DOI":"10.3109\/07853890.2015.1042908"},{"key":"ref-35","doi-asserted-by":"crossref","unstructured":"Sabeti S, Exner M, Mlekusch W, Amighi J, Quehenberger P, Rumpold H, et al. Prognostic impact of fibrinogen in carotid atherosclerosis: Nonspecific indicator of inflammation or independent predictor of disease progression? Stroke 2005;36:1400-4. doi: 10.1161\/01.STR.0000169931.96670.fc.","DOI":"10.1161\/01.STR.0000169931.96670.fc"},{"key":"ref-36","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 2014;8:494-500. doi: 10.1016\/j.jacl.2014.07.001.","DOI":"10.1016\/j.jacl.2014.07.001"},{"key":"ref-37","doi-asserted-by":"crossref","unstructured":"Yurtseven E, Ural D, Baysal K, Tokg\u00f6zo\u011flu L. An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb 2020;27:909-18. doi: 10.5551\/ jat.55400.","DOI":"10.5551\/jat.55400"},{"key":"ref-38","doi-asserted-by":"crossref","unstructured":"Fang C, Luo T, Lin L. Elevation of serum Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.  Ann Transl Med 2018;6:452. doi: 10.21037\/ atm.2018.11.04.","DOI":"10.21037\/atm.2018.11.04"},{"key":"ref-39","doi-asserted-by":"crossref","unstructured":"Ministrini S, Carbone F. PCSK9 and inflammation: Their role in autoimmune diseases, with a focus on rheumatoid arthritis and systemic lupus erythematosus. Curr Med Chem 2022;29:970-9. doi: 10.2174\/09298 67328666210810150940.","DOI":"10.2174\/0929867328666210810150940"},{"key":"ref-40","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-P\u00e9rez H, Quevedo-Abeledo JC, TejeraSegura B, de Armas-Rillo L, R\u00faa-Figueroa I, Gonz\u00e1lez-Gay MA, et al. Proprotein convertase subtilisin\/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis 2020;12:1759720X20975904. doi: 10.1177\/1759720X20975904.","DOI":"10.1177\/1759720X20975904"},{"key":"ref-41","doi-asserted-by":"crossref","unstructured":"Liu A, Rahman M, Hafstr\u00f6m I, Ajeganova S, Frosteg\u00e5rd J. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. Lupus 2020;29:825-35. doi: 10.1177\/0961203320926253.","DOI":"10.1177\/0961203320926253"},{"key":"ref-42","unstructured":"Fang C, Luo T, Chen X, Lin L. Elevated level of serum PCSK9 in patients with systemic lupus erythematosus. 2018;34:541-5."},{"key":"ref-43","unstructured":"Ferraz-Amaro I, Delgado-Fr\u00edas E, Hern\u00e1ndezHern\u00e1ndez V, S\u00e1nchez-P\u00e9rez H, de Armas-Rillo L, Garc\u00eda-Dopico JA, et al. Proprotein convertase subtilisin\/kexin type 9 in patients with systemic sclerosis. Clin Exp Rheumatol 2020;38 Suppl 125:18-24."},{"key":"ref-44","doi-asserted-by":"crossref","unstructured":"Arida A, Legaki AI, Kravvariti E, Protogerou A, Sfikakis PP, Chatzigeorgiou A. PCSK9\/LDLR system and rheumatoid arthritis-related atherosclerosis. Front Cardiovasc Med 2021;8:738764. doi: 10.3389\/ fcvm.2021.738764.","DOI":"10.3389\/fcvm.2021.738764"}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1458\/2608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1458\/2609","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1458\/2608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:00:38Z","timestamp":1761210038000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,31]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2024.10625","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}